Companies › Healthcare

Pfizer PFE

HealthcareMarket cap $163B20 connections

Pfizer made the most important pharmaceutical product of our lifetimes - the COVID-19 mRNA vaccine (with BioNTech) that ended the acute pandemic. Post-COVID revenue normalization has been brutal. Its pipeline includes oncology (Paxlovid successor), vaccines, and rare disease drugs from the Seagen acquisition. Pfizer's manufacturing network and global distribution are unmatched in pharma.

Open Pfizer's Company Hub Simulate a merger Supply chain See it on the map

Suppliers 9

Companies that sell to Pfizer

  • Thermo FisherHealthcare · $250BLab equipment for drug manufacturing
  • DanaherHealthcare · $158BBiotech instruments
  • CencoraHealthcare · $59BPharmaceutical distribution
  • Veeva SystemsTechnology · $45BVeeva Vault CRM for Pfizer commercial teams
  • IQVIAHealthcare · $45BClinical trial management
  • Waters CorporationHealthcare · $43BPfizer uses Waters HPLC for drug purity testing
  • West PharmaceuticalHealthcare · $26BWest stoppers in every Pfizer injectable vial
  • BrukerHealthcare · $10BPfizer uses Bruker instruments for drug analysis
  • DoximityHealthcare · $5BPfizer reaches doctors through Doximity platform

Partners 8

Strategic partnerships, joint products and alliances

  • ModernaHealthcare · $79BCompeting mRNA vaccine platforms
  • IQVIAHealthcare · $45BDrug development analytics
  • BioNTechHealthcare · $28BCOVID-19 vaccine development
  • Halozyme TherapeuticsHealthcare · $13BRoche uses Halozyme ENHANZE for subcutaneous drugs
  • Kymera TherapeuticsHealthcare · $9BSanofi $1.35B deal for Kymera IRAK4 degrader program
  • Ionis PharmaHealthcare · $7BAstraZeneca antisense drug partnership with Ionis
  • Dynavax TechnologiesHealthcare · $2BPfizer evaluates Dynavax CpG adjuvant for vaccines
  • ArvinasHealthcare · $500MPfizer $650M+ partnership on ARV-471 breast cancer PROTAC

Stakes owned 1

Companies Pfizer owns or has invested in

  • SeagenHealthcare · $43BPfizer completed $43B Seagen acquisition - ADC oncology expansionsince 2023

Competitors 4

Companies it competes with

  • Novo NordiskHealthcare · $430BDiabetes drug market
  • MerckHealthcare · $367BPharma rivals in oncology and vaccines
  • GSK plcHealthcare · $80BVaccine and drug rivalry
  • ModernaHealthcare · $79BmRNA vaccine rivalry

Key relationships in depth

Pfizer & Merck

Pfizer and Merck are two of the largest US pharmaceutical companies competing across oncology, vaccines, and infectious disease. Merck's Keytruda (pembrolizumab) is the world's best-selling drug at $25B+ in 2024 annual revenue, while Pfizer's oncology portfolio (Ibrance, Xtandi, Padcev) competes in adjacent cancer indications. Both companies also compete in vaccines: Pfizer's Prevnar franchise versus Merck's vaccines portfolio.

Why it matters: Cancer is the largest and fastest-growing pharmaceutical market, projected to exceed $300B by 2030. Keytruda's dominance across 30+ cancer indications has transformed Merck's revenue profile, while Pfizer's Seagen acquisition (completed 2023 for $43B) bolstered its oncology portfolio with antibody-drug conjugates. The competition for oncologist prescribing habits determines billions in revenue.

Pfizer & Moderna

Moderna and Pfizer were the two pioneer companies that brought mRNA vaccines to market during the COVID-19 pandemic, splitting the US mRNA vaccine market between Moderna's mRNA-1273 (Spikevax) and Pfizer-BioNTech's BNT162b2 (Comirnaty). The two companies now compete across respiratory vaccines (COVID, flu, RSV) and cancer vaccines using the same mRNA technology platform.

Why it matters: Pfizer earned over $100B from COVID vaccines and treatments (2021-2023), funding a massive pipeline expansion. Moderna, valued at $200B+ at peak, is now competing to extend mRNA beyond COVID into influenza, RSV, personalized cancer vaccines, and rare disease. The mRNA platform race will determine which company becomes the dominant vaccine and biologics franchise of the next decade.

Other Healthcare companies

Embed this on your site

Show Pfizer's network in an article or report - it updates as our data does.

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.